bioAffinity Technologies Announces Progress on CyPath® Lung Surveillance

What Happened
bioAffinity Technologies, Inc. (a Delaware corporation) filed a Form 8-K on September 1, 2026 to report a press release announcing that the company is advancing the potential application of its CyPath® Lung test for the surveillance of lung cancer patients. The press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: September 1, 2026 (Form 8-K, Item 8.01: Other Events).
• Announcement: advancing potential application of the CyPath® Lung test specifically for surveillance of lung cancer patients.
• Press release included as Exhibit 99.1 in the 8-K.

Why It Matters
This disclosure notifies investors that bioAffinity is working to expand the intended use of its CyPath® Lung test into post-diagnosis surveillance, which is part of the company’s clinical and commercial development efforts. While the filing does not provide clinical data, regulatory approvals, or financial impacts, investors tracking product development, regulatory milestones, or future commercial opportunities may view this as a progress update to monitor in subsequent filings and press releases.